Abstract
Diabetic nephropathy is a major cause of chronic renal failure. The evidence available indicates that renal hemodynamics are altered in clinical and experimental diabetes mellitus. In these circumstances, an increased glomerular filtration rate (GFR) is associated with albuminuria and eventually with glomerulosclerosis. We studied the renal and hemodynamic effects of long-term treatment (5 months) using an angiotensin-converting enzyme inhibitor (trandolapril, 0.7 mg/g b.w. per day) and a calcium antagonist (verapamil, 20 mg/g b.w. per day), and the combination of the two (veratran) at the same dose, on streptozotocin-diabetic uninephrectomized rats. A moderate degree of hyperglycemia (2–4 g/l) was maintained with daily insulin. Mean arterial pressure (MAP) was measured monthly using the tail-cuff method. Determinations were made of urinary protein excretion, creatinine clearance, urinary electrolyte excretion and, at the end of treatment, renal and cardiac hypertrophy. MAP was similar in control and untreated diabetic rats. Trandolapril and veratran reduced MAP whereas verapamil alone had no effect on these animals. All groups showed a slight proteinuria that increased with verapamil treatment. The GFR of diabetic animals was higher than in the control group (mainly the first 2 months), except for veratran group, in which it was similar to the control value. Urinary electrolyte excretion increased in all diabetic groups with no significant differences among them. Veratran induced a protective effect against cardiac hypertrophy. None of the treatments affected renal hypertrophy. It is concluded that in a murine model of diabetes without hypertension or proteinuria, a combination of verapamil and trandolapril prevents hyperfiltration whereas verapamil alone increases proteinuria.
Similar content being viewed by others
References
Anderson S, Renke HG, Brenner BM (1992) Nifedipine versus fosinopril in unineph-rectomized diabetic rats. Kidney Int 41:891–897
Bakris GL (1993) Hypertension in the diabetic patient: an overview of interventional studies to preserve renal function. Am J Hypertens 6[Suppl]:140–147
Bonsnes RW, Tausski HA (1945) The colorimetric determination of creatinine by the Jaffé reaction. J Biol Chem 158:581
Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye-binding. Anal Biochem 72:248–254
Brown SA, Walton CL, Crawford P, Bakris GL (1993) Long term effects of antihypertensive regimens on renal hemodynamics and proteinuria. Kidney Int 43:1210–1218
Brunner FP, Thiel G, Hermle M, Bock HA, Mihatsch MJ (1989) Long-term enalapril and verapamil in rats with reduced renal mass. Kidney Int 36:969–977
Davis MJ, Donovitz JA, Hood JD (1992) Stretch-activated single-channel and whole cell currents in vascular smooth muscle cells. Am J Physiol 262:C1083–C1088
DCCT Group (1993) The effects of intensive insulin treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986
Dworkin LD, Benstein JA, Parker M, Tolbert E, Feiner HD (1993) Calcium antagonists and converting enzyme inhibitors reduce renal injury by different mechanisms. Kidney Int 43:804–814
Dworkin LD, Levin RL, Benstein JA (1990) Effects of nifedipine and enalapril on glomerular injury in rats with deoxycorticosterone-salt hypertension. Am J Physiol 259:F598–F604
Dworkin LD, Parker M, Feiner HD, Tolbert E (1988) Renal protective actions of nifedipine and enalapril: averting the hypertrophied hypertensive glomerulus (abstract). Kidney Int 37:504
Epstein M (1991) Calcium antagonists and the kidney: implications for renal protection. J Cardiovasc Pharm 18[Suppl 10]:S64–S70
Hoelscher D, Bakris G (1994) Antihypertensive therapy and progression of diabetic renal disease. J Cardiovasc Pharmacol 23[Suppl 1]:S34–S38
Harris DCH, Hammond WS, Burke TJ, Schrier RW (1987) Verapamil protects against progression of experimental chronic renal failure. Kidney Int 31:41–46
Hostetter TH, Troy JL, Brenner BM (1981) Glomerular hemodynamics in experimental diabetes mellitus. Kidney Int 19:410–415
Jackson B, Debrevi L, Cubela R, Whitty M, Johnston CI (1986) Preservation of renal function in the rat remnant kidney model of chronic failure by blood pressure reduction. Clin Exp Pharmacol Physiol 13:319–323
Kleinman KS, Fine LG (1988) Prognostic implications of renal hypertrophy in diabetes mellitus. Diabetes 4:179–189
López-Farré A, Gómez-Garre DN, Bernabeu F, López-Novoa JM (1991) A role for endothelin in the maintenance of postischemic acute renal failure. J Physiol (Lond) 444:513–522
Loutzenhiser R, Epstein M (1985) Effects of calcium antagonists on renal hemodynamics. Am J Physiol 249:F619–F629
Loutzenhiser R, Epstein M (1990) The renal hemodynamic effects of calcium antagonists. In: Epstein M, Loutzenhiser R (eds) Calcium antagonists and the kidney. Hanley and Belfus, Philadelphia, pp 33–74
Mogensen CE (1987) Microalbuminuria as a predictor of clinical diabetic nephropathy. Kidney Int 31:673–689
Montero A, González-Sarmiento R, Rodríguez-López A, López Novoa JM (1995) Effect of verapamil on endothelin-1-induced proliferation in cultured rat mesangial cells. Cell Physiol Biochem 5:155–166
Omata K, Kanazawa M, Sato T, Abe F, Saito T, Abe K (1996) Therapeutic advantages of angiotensin converting enzyme inhibitors in chronic renal disease. Kidney Int 49[Suppl 55]:S57–S62
Pfeffer JM, Pfeffer MA, Frohlich ED (1971) Validity of an indirect tail-cuff method for determining systolic arterial pressure in unanesthetized normotensive and spontaneously hypertensive rats. J Lab Clin Med 78:957–962
Raij L, Keane WF (1985) Glomerular mesangium: its function and relationship to angiotensin II. Am J Med 79[Suppl 3C]:24–30
Remuzzi A, Ruggenenti P, Mosconi L, Pata V, Viberti G, Remuzzi G (1993) Effect of low-dose enalapril on glomerular size-selectivity in human diabetic nephropathy. J Nephrol 6:36–43
Ritz E, Hasslacher C, Tschope W, Koch M, Mann JFE (1987) Hypertension in diabetes mellitus. Contrib Neprol 54:77–85
Rosenthal T, Rosenmann E, Cohen AM (1990) Effects of nisoldipine on hypertension and glomerulosclerosis in Cohen diabetic rats with Goldblatt hypertension (abstract). Am J Hypertens 3:27
Tolins JP, Shultz P, Raij L (1988) Mechanisms of hypertensive glomerular injury. Am J Cardiol 62:54G–58G
Wen SF, Huang TP, Moorthy AV (1985) Effects of low protein diet on experimental diabetic nephropathy in the rat. J Lab Clin Med 106:589–597
Wolf G, Neilson EG (1993) Angiotensin II as a renal growth factor. J Am Soc Nephrol 3:1531–1540
Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM (1986) Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77:1925–1930
Zatz R, Meyer TW, Renke HG, Brenner BM (1985) Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc Natl Acad Sci USA 82:5963–5967
US Department of Health and Human Services (1985) Guide for the Care and Use of Laboratory Animals. NIH Publication No 80-23, rev. National Institutes of Health, Bethesda, Md
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gallego, B., Flores, O., López-Novoa, J.M. et al. Renal effects of antihypertensive therapy in uninephrectomized diabetic rats. Res. Exp. Med. 197, 199–209 (1997). https://doi.org/10.1007/s004330050069
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s004330050069